These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 8575145)

  • 41. Polymyalgia rheumatica and giant cell arteritis--An ophthalmic emergency.
    Durkin SR; Athanasiov PA; Crompton JL
    Aust Fam Physician; 2006 Nov; 35(11):889-91. PubMed ID: 17099810
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Polymyalgia rheumatica].
    Nishikai M
    Nihon Rinsho; 1999 Feb; 57(2):370-3. PubMed ID: 10078007
    [TBL] [Abstract][Full Text] [Related]  

  • 43. MMP-3 can distinguish isolated PMR from PMR with GCA: A retrospective study regarding PMR and GCA in Japan.
    Fukui S; Nunokawa T; Kobayashi S; Kamei S; Yokogawa N; Takizawa Y; Shimada K; Sugii S; Setoguchi K
    Mod Rheumatol; 2016; 26(2):259-64. PubMed ID: 26156043
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Plasma adrenomedullin levels in patients with polymyalgia rheumatica and giant cell arteritis.
    Garcia-Unzueta MT; Martínez-Taboada VM; Amado-Señarís JA; Rodríguez-Valverde V
    Clin Exp Rheumatol; 2006; 24(2 Suppl 41):S6-9. PubMed ID: 16859588
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Giant cell arteritis, polymyalgia rheumatica, and late-onset rheumatoid arthritis: Can they be components of a single disease process in elderly patients?
    Korkmaz C; Yıldız P
    Eur J Rheumatol; 2017 Jun; 4(2):157-160. PubMed ID: 28638694
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Classification/diagnostic criteria for GCA/PMR.
    Hunder GG
    Clin Exp Rheumatol; 2000; 18(4 Suppl 20):S4-5. PubMed ID: 10948747
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Polymyalgia rheumatica vs late-onset rheumatoid arthritis.
    Cutolo M; Cimmino MA; Sulli A
    Rheumatology (Oxford); 2009 Feb; 48(2):93-5. PubMed ID: 18658202
    [No Abstract]   [Full Text] [Related]  

  • 48. Large-vessel involvement in giant cell arteritis and polymyalgia rheumatica.
    Muratore F; Pazzola G; Pipitone N; Boiardi L; Salvarani C
    Clin Exp Rheumatol; 2014; 32(3 Suppl 82):S106-11. PubMed ID: 24854380
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Inflammatory Muscle Pain: Polymyalgia Rheumatica with or without Large Vessel Vasculitis].
    Schmidt WA
    Dtsch Med Wochenschr; 2020 Jul; 145(13):895-902. PubMed ID: 32615604
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Intercellular adhesion molecule 1 gene polymorphisms in polymyalgia rheumatica/giant cell arteritis: association with disease risk and severity.
    Salvarani C; Casali B; Boiardi L; Ranzi A; Macchioni P; Nicoli D; Farnetti E; Brini M; Portioli I
    J Rheumatol; 2000 May; 27(5):1215-21. PubMed ID: 10813290
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The spectrum of polymyalgia rheumatica in northwestern Spain: incidence and analysis of variables associated with relapse in a 10 year study.
    González-Gay MA; García-Porrúa C; Vázquez-Caruncho M; Dababneh A; Hajeer A; Ollier WE
    J Rheumatol; 1999 Jun; 26(6):1326-32. PubMed ID: 10381051
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Polymyalgia rheumatica and temporal arteritis].
    Vos PA; Bijlsma JW; Derksen RH
    Ned Tijdschr Geneeskd; 2005 Aug; 149(35):1932-7. PubMed ID: 16159030
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Polymyalgia rheumatica and temporal arteritis: managing older patients.
    Pereira M; Kaine JL
    Geriatrics; 1986 Jun; 41(6):54-5, 59-60, 63 passim. PubMed ID: 3710167
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Assessment of the New 2012 EULAR/ACR Clinical Classification Criteria for Polymyalgia Rheumatica: A Prospective Multicenter Study.
    Ozen G; Inanc N; Unal AU; Bas S; Kimyon G; Kisacik B; Onat AM; Murat S; Keskin H; Can M; Mengi A; Cakir N; Balkarli A; Cobankara V; Yilmaz N; Yazici A; Dogru A; Sahin M; Sahin A; Gok K; Senel S; Pamuk ON; Yilmaz S; Bayindir O; Aksu K; Cagatay Y; Akyol L; Sayarlioglu M; Yildirim-Cetin G; Yasar-Bilge S; Yagci I; Aydin SZ; Alibaz-Oner F; Atagunduz P; Direskeneli H
    J Rheumatol; 2016 May; 43(5):893-900. PubMed ID: 26834222
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Predictors for treatment success and expression of glucocorticoid receptor in giant cell arteritis and polymyalgia rheumatica.
    Braun N; Fritz P; Rieth A; Schroth W; Kimmel M; Biegger D; Zakim D; Alscher MD
    J Rheumatol; 2009 Oct; 36(10):2269-76. PubMed ID: 19684157
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Genetic markers of disease susceptibility and severity in giant cell arteritis and polymyalgia rheumatica.
    González-Gay MA; Amoli MM; Garcia-Porrua C; Ollier WE
    Semin Arthritis Rheum; 2003 Aug; 33(1):38-48. PubMed ID: 12920695
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Do steroids increase lymphoma risk? A case-control study of lymphoma risk in polymyalgia rheumatica/giant cell arteritis.
    Askling J; Klareskog L; Hjalgrim H; Baecklund E; Björkholm M; Ekbom A
    Ann Rheum Dis; 2005 Dec; 64(12):1765-8. PubMed ID: 15843445
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Polymyalgia rheumatica.
    Lestico MR; Boh LE; Schuna AA
    Clin Pharm; 1993 Aug; 12(8):571-80. PubMed ID: 8222521
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clinical outcome of 149 patients with polymyalgia rheumatica and giant cell arteritis.
    Bahlas S; Ramos-Remus C; Davis P
    J Rheumatol; 1998 Jan; 25(1):99-104. PubMed ID: 9458211
    [TBL] [Abstract][Full Text] [Related]  

  • 60. High angiopoietin-2 levels associate with arterial inflammation and long-term glucocorticoid requirement in polymyalgia rheumatica.
    van Sleen Y; Boots AMH; Abdulahad WH; Bijzet J; Sandovici M; van der Geest KSM; Brouwer E
    Rheumatology (Oxford); 2020 Jan; 59(1):176-184. PubMed ID: 31292652
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.